Vaccinex, Inc. Proceeds from Sale and Maturity of Marketable Securities
Vaccinex, Inc. (VCNX) reported Proceeds from Sale and Maturity of Marketable Securities of $14.15 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2021-03-31
- Vaccinex, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2019-12-31 was $1.00K.
- Vaccinex, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2019-09-30 was $0.00.
- Vaccinex, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2019-06-30 was $2.35M.
- Vaccinex, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2019-03-31 was $11.80M.
- Vaccinex, Inc. proceeds from sale and maturity of marketable securities for fiscal 2019 was $14.15M, a 109.64% increase from fiscal 2018.
- Vaccinex, Inc. proceeds from sale and maturity of marketable securities for fiscal 2018 was $6.75M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $1.00K derived: sum of 2 quarters · filed 2021-03-31 | $2.35M derived: sum of 3 quarters · filed 2021-03-31 | $14.15M 10-K · filed 2021-03-31 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $2.35M derived: sum of 2 quarters · filed 2020-11-13 | $14.15M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $14.15M 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $11.80M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $6.75M 10-K · filed 2020-03-09 |